Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual Zolpidem for Long-Term Treatment of Chronic Insomnia
NCT05456152Phase 3Not yet recruiting
- Sponsor
- EMS
- Start
- Jun 2024
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zolpidem sublingual tablet in Insomnia, sponsored by EMS. Primary endpoint: Safety profile of sublingual zolpidem at 60 days. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
zolpidem sublingual tablet
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT05456152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05456152.